Dare Bioscience   Report issue

For profit Phase 2
Founded: San Diego CA United States (2005)
Status: No NME R&D (2005)

Organization Overview

First Clinical Trial
None
First Marketed Drug
2021
clindamycin (cleocin)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

DARE | Dare Bioscience | Dare Bioscience, Inc.

Active Ingredients

Marketed Drugs (1)

clindamycin (cleocin) (2021)

Drugs in Phase 2 Trials (2)

Key: Dare Bioscience (0) Acquired (2)

capecitabine (xeloda) (1 trial)

it-101 (1 trial)

Indications

Overview

  • Highest Phase: None
  • # of Trials: 1
  • # of Trial APIs: 2